Alfasigma Acquires Exclusive Rights to Adibelivir for HSV Encephalitis in €125 Million Deal
Key Insights
Alfasigma (search) secured exclusive worldwide licensing rights to the parenteral formulation of adibelivir (search), a next-generation helicase-primase (search) inhibitor, for treating HSV encephalitis (search) through a strategic partnership with Innovative Molecules (search).
The deal includes up to €125 million in upfront and milestone payments, while the parenteral formulation has received approval to enter Phase 1 clinical development for this ultra-rare neurological condition.
HSV encephalitis (search) affects 1 in 250,000-500,000 individuals but carries high mortality and substantial risk of permanent neurological impairment, representing a critical unmet medical need.
Alfasigma (search) S.p.A., a global pharmaceutical company, has entered into a strategic partnership with clinical-stage biotechnology company Innovative Molecules (search) GmbH to secure exclusive worldwide licensing rights to the parenteral formulation of adibelivir (search) for treating Herpes Simplex Virus (HSV) encephalitis. The agreement, announced on January 14, 2026, includes Alfasigma's investment in Innovative Molecules and licensing terms worth up to €125 million.
Novel Therapeutic Approach for Ultra-Rare Disease
Adibelivir (search), formerly known as IM 250, represents a next-generation helicase-primase (search) inhibitor designed to address the critical unmet medical need in HSV encephalitis (search) treatment. The parenteral formulation has received approval to enter Phase 1 clinical development specifically for HSV encephalitis, while the oral formulation continues advancing toward Phase 2 development for genital herpes (search).
HSV encephalitis (search) presents as a clinically devastating neurological disease with high mortality rates and substantial risk of permanent neurological impairment among survivors. Despite decades of use, existing antiviral therapies have not meaningfully improved outcomes, highlighting the urgent need for therapeutic innovation in this indication.
Addressing Significant Disease Burden
Although HSV encephalitis (search) has a low incidence rate, estimated at 1 case per 250,000 to 500,000 individuals, the disease burden remains profound. The condition's severe and life-threatening nature underscores the urgent need for innovative treatments capable of improving patient outcomes.
Adibelivir (search) functions as a long-acting helicase (search) inhibitor and is being investigated for its potential to improve viral control and impact clinical outcomes, including survival and long-term neurological sequelae. This mechanism of action represents a differentiated approach to treating HSV infections compared to existing therapeutic options.
Strategic Partnership Details
Under the licensing agreement, Alfasigma (search) obtains exclusive global rights to develop, manufacture, and commercialize the parenteral formulation of adibelivir (search) specifically for HSV encephalitis (search). Innovative Molecules (search) retains full rights to all other formulations, including the oral version currently in development for genital herpes (search).
The financial terms include payments of up to €125 million structured as upfront and milestone payments. These payments will be triggered by development progress, regulatory approvals, and achievement of global commercial milestones.
Francesco Balestrieri, CEO of Alfasigma (search), emphasized the strategic fit: "With a focus on rare and specialty care, at Alfasigma we aim to drive growth by developing and delivering innovative solutions that address complex healthcare needs. We are well positioned to do so through our capabilities, expertise, and global footprint. Adibelivir (search) is exactly the kind of innovation we seek to develop and deliver to improve patient outcomes."
Accelerating Development Programs
The partnership provides mutual benefits for both companies' development programs. Florian Vogel, CEO of Innovative Molecules (search), noted: "This partnership represents a strong external validation of our differentiated approach to treating HSV infections and underscores the significant clinical and commercial potential of adibelivir (search). We are pleased to welcome Alfasigma (search) as a new investor in our company, as this capital infusion will accelerate the advancement of the oral formulation of adibelivir into a Phase 2 clinical development program for patients with genital herpes (search)."
The capital infusion from Alfasigma (search)'s investment will specifically support the advancement of the oral formulation into Phase 2 clinical trials for genital herpes (search), while Alfasigma focuses on developing the parenteral formulation for the ultra-rare HSV encephalitis (search) indication.
Company Profiles
Alfasigma (search), founded over 75 years ago and headquartered in Bologna and Milan, Italy, operates in over 100 markets across Europe, North and South America, Asia, and Africa. The company employs approximately 4,000 people and reported 2024 revenues of €1.87 billion. Alfasigma focuses on three main therapeutic areas: Gastroenterology, Vascular, and Rheumatology, with a portfolio spanning primary care to specialty care and rare disease medications.
Innovative Molecules (search) GmbH, based in Munich, Germany, specializes in developing transformative therapies for herpes simplex virus infections. The company's pipeline is dedicated to advancing novel antivirals that address severe and underserved patient populations. UBS (search) served as the exclusive financial adviser to Innovative Molecules for this transaction.